Trending Up0.1550 (14.3519%)
  • Bid / Lots
    1.1800/ 2
  • Ask / Lots
    1.2400/ 3
  • Open / Previous Close
    1.1650 / 1.0800
  • Day Range
    Low 0.9800
    High 1.2900
  • 52 Week Range
    Low 0.5347
    High 2.8400
  • Volume
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 1.08
09:53 ET3221.08
11:03 ET2001.095
11:05 ET4001.104
11:12 ET1001.1
11:14 ET1001.11
11:16 ET11001.1424
11:21 ET10061.1225
11:23 ET10001.1225
11:27 ET15991.13
11:41 ET2001.1198
12:17 ET1501.09
01:04 ET1001.09
01:24 ET2001.1
01:26 ET1001.1
01:38 ET30634901.08
01:42 ET5001.085
01:44 ET7001.085
01:45 ET13501.085
01:47 ET14951.07
01:49 ET4001.08
01:51 ET6001.07
01:56 ET14881.1
02:02 ET6001.11
02:03 ET1001.096
02:18 ET2001.11
02:20 ET9001.11
02:21 ET3001.1
02:23 ET15001.12
02:27 ET7001.14
02:30 ET4001.14
02:32 ET30751.21
02:34 ET30661.24
02:36 ET44111.24
02:38 ET16001.24
02:39 ET30501.23
02:41 ET19451.25
02:43 ET48341.23
02:45 ET42501.28
02:48 ET36001.29
02:50 ET53501.25
02:52 ET34941.25
02:54 ET36001.25
02:56 ET16001.25
02:57 ET15001.25
02:59 ET6501.22
03:14 ET5001.19
03:15 ET6001.2
03:21 ET41001.18
03:24 ET9831.18
03:44 ET1001.19
03:46 ET4501.2
03:51 ET4001.19
03:55 ET6001.235
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesCNTB
Connect Biopharma Holdings Ltd
United StatesASLN
Aslan Pharmaceuticals Ltd
United StatesNDRA
ENDRA Life Sciences Inc
United StatesBWVI
Psycheceutical Bioscience Inc
United StatesBUDZ
Weed Inc
United StatesFWBI
First Wave BioPharma Inc
As of 2024-02-25

Company Information

Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the treatment of T cell-driven inflammatory diseases. The Company’s lead product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha (IL-4Ra) in development for the treatment of atopic dermatitis and asthma. Its second advanced product candidate, CBP-307, is a modulator of S1P1 T cell receptor and is in development for the treatment of ulcerative colitis (UC). The Company’s third product candidate, CBP-174, is a peripherally acting antagonist of histamine receptor 3, in development for the treatment of pruritus associated with atopic dermatitis (AD). It has clinical development activities in the United States, the People’s Republic of China (PRC), Europe, and Australia and operations in those geographies, as well as Hong Kong. Its subsidiaries include Connect Biopharma HongKong Limited, Connect Biopharm LLC and others.

Contact Information

12265 El Camino Real, Suite 350SAN DIEGO, CA, United States 92130


Chairman of the Board, President, Co-Founder
Wubin Pan
Chief Executive Officer, Co-Founder, Director
Zheng Wei
Chief Financial Officer
Steven Chan
Chief Business Officer
Selwyn Ho
Chief Medical Officer
Chin Lee

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
Revenue (TTM)
Shares Outstanding
Dividend Yield
Annual Dividend Rate
Ex-Dividend Date
Pay Date
Book Value
P/E Ratio
Price/Sales (TTM)
Price/Cash Flow (TTM)
Operating Margin
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.